

April 8, 2019

Listing Department
BSE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai-400 001

Code: 532 321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: CADILAHC

Re.: Press Release.

Dear Sir / Madam,

Please find enclosed a copy of press release dated April 8, 2019 titled "Zydus receives tentative approval from the USFDA for Lacosamide Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**


DHAVAL N. SONI
COMPANY SECRETARY



Encl.: As above

Zydus receives tentative approval from the USFDA for Lacosamide Tablets

Ahmedabad, 8 April, 2019

Zydus Cadila has received the tentative approval from the USFDA to market Lacosamide Tablets (US RLD – Vimpat®) in the strengths of 50 mg, 100 mg, 150 mg and 200 mg. Lacosamide is an anticonvulsant or antiepileptic drug, used to prevent and control seizures. It works by reducing the spread of seizure activity in the brain. The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has 261 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
